Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors

Cellular Oncology

Volumn 32, Issue 5-6, 2010, Pages 361-372

  Lucci, Maria Antonietta ^a   Orlandi, Rosaria ^b   Triulzi, Tiziana ^b   Tagliabue, Elda ^b   Balsari, Andrea ^c   Villa Moruzzi, Emma ^a  

^a UNIVERSITY OF PISA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

array analysis; breast cancer; HER2; phosphorylation; Tyrosine phosphatases

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 3; DUAL SPECIFICITY PHOSPHATASE 10; DUAL SPECIFICITY PHOSPHATASE 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE PHOSPHATASE; PHOSPHATASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOPROTEIN PHOSPHATASE CDC14; PROTEIN MYOTUBULARIN RELATED PHOSPHATASE; PROTEIN MYOTUBULARIN RELATED PHOSPHATASE 11; PROTEIN PTP4; PROTEIN PTPN18; PROTEIN PTPRA; PROTEIN PTPRK; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL; DNA MICROARRAY; DOWN REGULATION; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; DATABASES, GENETIC; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROTEIN TYROSINE PHOSPHATASES; RECEPTOR, ERBB-2; TRANSGENES; TUMOR MARKERS, BIOLOGICAL;

EID: 77953992438     PISSN: 15705870     EISSN: None     Source Type: Journal    
DOI: 10.3233/CLO-2010-0520     Document Type: Article

References (44)

1. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, A. Osterman, A. Godzik, T. Hunter, J. Dixon and T. Mustelin, Protein ty-rosine phosphatases in the human genome, Cell 117 (2004), 699-711.
2. J.N. Andersen, P.G. Jansen, S.M. Echwald, O.H. Mortensen, T. Fukada, R. Del Vecchio, N.K. Tonks and N.P. Moller, A genomic perspective on protein tyrosine phosphatases: gene structure, pseudogenes and genetic disease linkage, FA S E B J. 18 (2004), 8-30.
3. C.L. Arteaga, EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugs, J. Clin. Oncol. 21 (2003), 289-291.
4. M. Bentires-Alj and B.G. Neel, Protein-tyrosine phosphatase 1B is required for HER2/Neu-induced breast cancer, Cancer Res. 67 (2007), 2420-2424.
5. D.C. Bessette, D. Qiu and C.J. Pallen, PRL PTPs: mediators and markers of cancer progression, Cancer Metastasis Rev. 27 (2008), 231-252.
6. R. Boutros, C. Dozier and B. Ducommun, The when and wheres of CDC25 phosphatases, Curr. Opin. Cell Biol. 18 (2006), 185-191.
7. M. Campiglio, A. Locatelli, C. Olgiati, N. Normanno, G. Somenzi, L. Vigano, M. Fumagalli, S. Menard and L. Gianni, Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 ("Iressa") is independent of EGFR expression level, J. Cell. Physiol. 198 (2004), 259-268.
8. M. Campiglio, G. Somenzi, C. Olgiati, G. Beretta, A. Balsari, N. Zaffaroni, P. Valagussa and S. Menard, Role of proliferation in HER2 status predicted response to doxorubicin, Int. J. Cancer 105 (2003), 568-573.
9. C.J. Caunt, S.P. Armstrong, C.A. Rivers, M.R. Norman and C.A. McArdle, Spatiotemporal regulation of ERK2 by dual specificity phosphatases, J. Biol. Chem. 283 (2008), 26612-26623.
10. M. Gensler, M. Buschbeck and A. Ullrich, Negative regulation of HER2 signaling by the PEST-type protein-tyrosine phos-phatase BDP1, J. Biol. Chem. 279 (2004), 12110-12116.
11. S. Granot-Attas and A. Elson, Protein tyrosine phosphatase ep-silon activates Yes and Fyn in Neu-induced mammary tumor cells, Exp. Cell Res. 294 (2004), 236-243.
12. D. Harari and Y. Yarden, Molecular mechanisms underlying ErbB2/HER2 action in breast cancer, Oncogene 19 (2000), 6102-6114.
13. N.E. Hynes and G. Macdonald, ErbB receptors and signaling pathways in cancer, Curr. Opin. Cell Biol. 21 (2009), 177-184.
14. S.M. Keyse, Dual-specificity MAP kinase phosphatases (MKPs) and cancer, Cancer Metastasis Rev. 27 (2008), 253-261.
15. M. Larsen, M.L. Tremblay and K.M. Yamada, Phosphatases in cell-matrix adhesion and migration, Nat. Rev. Mol. Cell Biol. 4 (2003), 700-711.
16. S.W. Lee, C.L. Reimer, L. Fang, M.L. Iruela-Arispe and S.A. Aaronson, Overexpression of kinase-associated phosphatase (KAP) in breast and prostate cancer and inhibition of the transformed phenotype by antisense KAP expression, Mol. Cell. Biol. 20 (2000), 1723-1732.
17. B. Linggi and G. Carpenter, ErbB receptors: new insights on mechanisms and biology, Trends Cell Biol. 16 (2006), 649-656.
18. O. Lorenzo, S. Urbe and M.J. Clague, Systematic analysis of myotubularins: heteromeric interactions, subcellular localisation and endosome related functions, J. Cell Sci. 119 (2006), 2953-2959.
19. S. Menard, S.M. Pupa, M. Campiglio and E. Tagliabue, Biologic and therapeutic role of HER2 in cancer, Oncogene 22 (2003), 6570-6578.
20. M.M. Moasser, A. Basso, S.D. Averbuch and N. Rosen, The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells, Cancer Res. 61 (2001), 7184-7188.
21. M.G. Mohi and B.G. Neel, The role of Shp2 (PTPN11) in cancer, Curr. Opin. Genet. Dev. 17 (2007), 23-30.
22. B. Naume, X. Zhao, M. Synnestvedt, E. Borgen, H. Gierck-sky Russnes, O.C. Lingjærde, M. Strømberg, G. Wiedswang, G. Kvalheim, R. Kåresen, J.M. Nesland, A.L. Børresen-Dale and T. Sørlie, Presence of bone marrow micrometastasis is associated with different recurrence risk within molecular subtypes of breast cancer, Mol. Oncol. 1 (2007), 160-171.
23. B.G. Neel, H. Gu and L. Pao, The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling, Trends Biochem. Sci. 28 (2003), 284-293.
24. D.M. Owens and S.M. Keyse, Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases, Oncogene 26 (2007), 3203-3213.
25. P.P. Pandolfi, Breast cancer-loss of PTEN predicts resistance to treatment, N. Engl. J. Med. 351 (2004), 2337-2338.
26. I. Radke, M. Gotte, C. Kersting, B. Mattsson, L. Kiesel and P. Wulfing, Expression and prognostic impact of the protein ty-rosine phosphatases PRL-1, PRL-2 and PRL-3 in breast cancer, Br. J. Cancer 95 (2006), 347-354.
27. F.L. Robinson and J.E. Dixon, Myotubularin phosphatases: policing 3-phosphoinositides, Trends Cell Biol. 16 (2006), 403-412.
28. D.J. Slamon, Studies of the HER-2/neu proto-oncogene in human breast cancer, Cancer Invest. 8 (1990), 253.
29. D.J. Slamon, G.M. Clark, S.G. Wong, W.J. Levin, A. Ullrich and W.L. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu onco-gene, Science 235 (1987), 177-182.
30. K.S. Spencer, D. Graus-Porta, J. Leng, N.E. Hynes and R.L. Klemke, ErbB2 is necessary for induction of carcinoma cell invasion by ErbB family receptor tyrosine kinases, J. Cell Biol. 148 (2000), 385-397.
31. E. Tagliabue, F. Castiglioni, C. Ghirelli, M. Modugno, L. As-naghi, G. Somenzi, C. Melani and S. Menard, Nerve growth factor cooperates with p185(HER2) in activating growth of human breast carcinoma cells, J. Biol. Chem. 275 (2000), 5388-5394.
32. N.K. Tonks, Protein tyrosine phosphatases: from genes, to function, to disease, Nat. Rev. Mol. Cell Biol. 7 (2006), 833-846.
33. N.K. Tonks and S.K. Muthuswamy, A brake becomes an accelerator: PTP1B-a new therapeutic target for breast cancer, Cancer Cell 11 (2007), 214-216.
34. M.J. van de Vijver, Y.D. He, L.J. van't Veer, H. Dai, A.A. Hart, D.W. Voskuil, G.J. Schreiber, J.L. Peterse, C. Roberts, M.J. Marton, M. Parrish, D. Atsma, A. Witteveen, A. Glas, L. De-lahaye, T. van der Velde, H. Bartelink, S. Rodenhuis, E.T. Rutgers, S.H. Friend and R. Bernards, A gene-expression signature as a predictor of survival in breast cancer, N. Engl. J. Med. 347 (2002), 1999-2009. (Pubitemid 35461656)
35. E. Villa-Moruzzi, Activation of the CDC25C phosphatase in mitotic HeLa cells, Biochem. Biophys. Res. Commun. 196 (1993), 1248-1254.
36. E. Villa-Moruzzi, S. Lapi, M. Prat, G. Gaudino and P.M. Comoglio, A protein tyrosine phosphatase activity associated with the hepatocyte growth factor/scatter factor receptor, J. Biol. Chem. 268 (1993), 18176-18180.
37. E. Villa-Moruzzi, F. Puntoni, A. Bardelli, E. Vigna, S. De Rosa and P.M. Comoglio, Protein tyrosine phosphatase PTP-S binds to the juxtamembrane region of the hepatocyte growth factor receptor met, Biochem. J. 336 (1998), 235-239.
38. Z. Wang, D. Shen, D.W. Parsons, A. Bardelli, J. Sager, S. Szabo, J. Ptak, N. Silliman, B.A. Peters, M.S. van der Hei-jden, G. Parmigiani, H. Yan, T.L. Wang, G. Riggins, S.M. Powell, J.K. Willson, S. Markowitz, K.W. Kinzler, B. Vogel-stein and V.E. Velculescu, Mutational analysis of the tyrosine phosphatome in colorectal cancers, Science 304 (2004), 1164-1166.
39. A. Wolf-Yadlin, N. Kumar, Y. Zhang, S. Hautaniemi, M. Za-man, H.D. Kim, V. Grantcharova, D.A. Lauffenburger and F.M. White, Effects of HER2 overexpression on cell signaling networks governing proliferation and migration, Mol. Syst. Biol. 2 (2006), 54.
40. Y. Yarden and M.X. Sliwkowski, Untangling the ErbB signalling network, Nat. Rev. Mol. Cell Biol. 2 (2001), 127-137.
41. J. Yu, D.G. Ryan, S. Getsios, M. Oliveira-Fernandes, A. Fatima and R.M. Lavker, MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia, Proc. Natl. Acad. Sci. USA 105 (2008), 19300-19305.
42. L. Zhan, B. Xiang and S.K. Muthuswamy, Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors, Cancer Res. 66 (2006), 5201-5208.
43. X.D. Zhou and Y.M. Agazie, Inhibition of SHP2 leads to mes-enchymal to epithelial transition in breast cancer cells, Cell Death Differ. 15 (2008), 988-996.
44. J.H. Zhu, R. Chen, W. Yi, G.T. Cantin, C. Fearns, Y. Yang, J.R. Yates 3rd and J.D. Lee, Protein tyrosine phosphatase PTPN13 negatively regulates Her2/ErbB2 malignant signaling, Onco-gene 27 (2008), 2525-2531.